Dispel Concerns About CV Safety With Sulfonylureas
December 2019
New evidence will provide more reassurance about the cardiovascular safety of sulfonylureas (gliclazide, etc) for type 2 diabetes.
There's been debate for years over whether sulfonylureas increase CV risk...mainly due to data with the old, first-generation tolbutamide.
And most sulfonylurea monographs warn of increased CV mortality.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive